A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management by Micheletto, Claudio et al.
R E V I EW
A Framework For Step Down Or Therapeutic
Re-Organization For Withdrawal Of Inhaled
Corticosteroids In Selected Patients With COPD:
A Proposal For COPD Management
This article was published in the following Dove Press journal:




Fabiano Di Marco 4
Pierachille Santus5
1Respiratory Unit, Azienda Ospedaliera
Universitaria Integrata, Verona, Italy;
2Department of Internal Medicine,
Respiratory Diseases and Allergy Clinic,
University of Genova, Azienda Policlinico
IRCCS San Martino, Genoa, Italy;
3Department of Medical Sciences,
University of Ferrara, Ferrara, Italy;
4Department of Health Sciences,
Università degli Studi di Milano,
Respiratory Unit, Papa Giovanni XXIII
Hospital, Bergamo, Italy; 5Department of
Health Sciences, Università degli Studi di
Milano,Pulmonary Unit, Luigi Sacco
University Hospital, ASST
Fatebenefratelli, Milan, Italy
Abstract: While chronic obstructive pulmonary disease (COPD) continues to be a major
cause of morbidity and mortality, pharmacological therapy has a definite benefit on symp-
toms as well as the frequency and severity of exacerbations, and general health. The most
recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple
therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] +
inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and
without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy
with ICS is not currently recommended, but may be considered in association with LABAs
in patients with a history of exacerbations and elevated eosinophils in spite of appropriate
treatment with long-acting bronchodilators. However, long-term use of ICS in combination
therapy has been associated with adverse effects, even if widely used in routine management
for decades. The available evidence suggests that ICS can be rationally discontinued in
patients with stable disease and is not likely to have unfavorable effects on lung function,
overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely
accepted that ICS therapy should be limited to a small proportion of patients after careful
assessment of the individual risk-benefit profile. Unfortunately, however, there are no inter-
national recommendations that provide specific guidance or a protocol for withdrawal of
ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is
proposed that can provide clinicians with a simple management scheme to guide the most
appropriate therapy for management of COPD and use of ICS. In management of COPD, a
highly personalized approach is advocated so that the most appropriate therapy for each
individual patient can be selected.
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Introduction
Despite advances in therapy, chronic obstructive pulmonary disease (COPD)
remains a major cause of both morbidity and mortality.1,2 Pharmacological therapy
for COPD has a definite positive impact on the disease as it can improve symptoms
and the frequency and severity of exacerbations, and ameliorate both exercise
tolerance and general health.3 At present, the principal options for management
of COPD include a relatively small number of drug classes, namely bronchodilators
(short- and long-acting beta2 agonists [SABAs, and LABAs], short- and
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long-acting muscarinic antagonists [SAMAs, and
LAMAs]), along with inhaled corticosteroids (ICSs) and
PDE-4 inhibitors.
The main goals of therapy for COPD are prevention
and control of symptoms, diminish both frequency and
severity of exacerbations, and to improve exercise toler-
ance and the overall quality of life. Monotherapy with a
long-acting bronchodilator has the potential to increase
lung function and symptoms, as well as enhance exercise
performance and reduce the number of exacerbations.4,5
Concomitant administration of LABA/LAMA significantly
improves lung function vs a single bronchodilator.6
The most recent update of the Global Initiative for
Obstructive Lung Disease (GOLD) recommends triple
therapy (ICS + LABA + LAMA) only for patients with
exacerbations and elevated eosinophil levels who are not
controlled with a LABA/LAMA or ICS/LABA
combination.3 Given that the agents used in triple therapy
all have dissimilar mechanisms of action, this provides the
basis for their concomitant use to optimize the prevention
of exacerbation and potential clinical benefits according to
pivotal studies.7,8 Today, triple therapy is used extensively,
and according to a recent review on general practice in the
UK over a 5-year period (2004 to 2009), the use of triple
therapy more than doubled in patients with very severe
COPD.9 Moreover, a real-world study in Italy showed that
6.3% of patients with newly diagnosed disease were pre-
scribed triple inhaled therapy with ICSs, and that 42% of
these patients initiated triple therapy at diagnosis; in that
study, older male gender and use of ICS/LABA FDC at
diagnosis appeared to correlate most with prescription of
triple therapy.10 In support of such a strategy, a recent
systematic review and meta-analysis concluded that, com-
pared to monotherapy or dual therapy, triple therapy is
associated with fewer moderate or severe exacerbations
of COPD and improved lung function.11
In the current GOLD recommendations, it is acknowl-
edged that there is a lack of high-quality evidence that
supports the initial strategies for pharmacological treat-
ment in patients with newly diagnosed COPD.3 In the
2019 GOLD update, ICS are now recommended as the
first choice only for some patients belonging to GOLD
group D, and only in combination with LABAs
(Figure 1).3 Long-term monotherapy with ICS is not pre-
sently recommended, but can be considered when asso-
ciated with LABAs in those with a history of
exacerbations and elevated eosinophils in spite of adequate
therapy with long-acting bronchodilators.3 However, it is
worthwhile noting that long-term use of ICS in either dual
or triple therapy has been associated with some complica-
tions and adverse effects,12–14 even if they are widely used
in routine management of patients for many years. As also
stated in the GOLD guidelines, ICS may increase the risk
of side effects including pneumonia.3 Thus, there remains
ongoing concern over the long-term use of ICS, despite
their recommend use when combined with long-acting
bronchodilators in individuals who are at increased risk
of exacerbation. Indeed, ICS are still routinely prescribed
to the most patients with COPD at high risk of exacerba-
tions and elevated eosinophils, even if GOLD criteria for
their administration are not met.15,16
Unfortunately, at present, there are no international
recommendations that provide specific guidance for depre-
scribing ICS, despite the evidence suggesting that they can
be withdrawn in many patients. Herein, the available evi-
dence on the use of ICS is reviewed before proposing a
simple management scheme to guide the most appropriate
therapy for management of COPD and use of ICS.
Figure 1 GOLD 2019 algorithms for initial pharmacological treatment of COPD. aConsider if highly symptomatic (e.g. CAT>20). bConsider if eosinophils > 300 cells/μL.
Note: Reprinted with permission from: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 Report. Available from: https://goldcopd.org/gold-reports/.
Accessed September 10, 2019.3 ©2019 Global Initiative for Chronic Obstructive Lung Disease. Available from: www.goldcopd.org.
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Patient Phenotypes And ICS
Withdrawal
Given the wide range of COPD patient phenotypes and
clinical presentations, with potentially diverse pathophy-
siological mechanisms, it is not likely that all patient
subtypes will benefit from ICS, which may in part explain
some of the discrepant results in the literature. There is, in
fact, increasing evidence that patients with some pheno-
types may benefit more than others from the addition of
ICS to treatment regimens. In particular, it appears likely
that those with asthma–COPD overlap (ACO), frequent
exacerbators, and those with eosinophilic inflammation
may benefit most from ICS.
Asthma–COPD Overlap
Although its prevalence is difficult to estimate, roughly
one-fourth of patients with COPD may be considered to
have ACO in which some feature of asthma and COPD
coexist without presenting as a distinct syndrome.17 In a
large analysis of over 5500 patients, among older indivi-
duals with COPD and asthma newly prescribed combina-
tion therapy with LABA and ICS led to a lower risk of
death or COPD hospitalization vs newly prescribed
LABAs alone.18 Real-world practice seems to confirm
this, as only 18% of patients with ACO are not routinely
given an ICS.19 Lee et al, have also provided clinical
evidence that patients with ACO and mild-to-moderate
limitations in airflow will show better lung function fol-
lowing treatment with an ICS/LABA combination after 3
months.20 Of note, in a database study of over 250,000
patients with ACO in Taiwan, use of LAMA or an ICS/
LABA combination was found to be associated with a
lessened risk for acute exacerbations.21 Expert opinion
seems to suggest that for patients without ACO, LAMA/
LABA may be appropriate for initiating therapy, while
those who still have exacerbations may require additional
treatments, possibly with ICS or PDE-4 inhibitors, taking
into consideration the risk-benefit ratio in individual
patients.22
Frequent Exacerbators And Eosinophilic
Inflammation
Frequent exacerbators are another well-represented sub-
class of patients with COPD. The risk of exacerbation is
normally defined according to the patient’s history of
exacerbations or the GOLD classification of airway limita-
tion (i.e., high risk is ≥2 exacerbations or ≥1
hospitalization per year). Even considering this definition,
many patients with moderate-to-severe COPD, or those
classified as GOLD stage C and D, are not frequent
exacerbators, and thus do not meet qualifications for ICS
therapy.17
The results from several studies have implicated that in
both chronic bronchitis and COPD there is a relation
between airway eosinophilia and exacerbations.23–26 In
addition, an association between eosinophilia in sputum
and response to steroids in COPD has been noted.27,28 In
those with acute exacerbations of COPD, the administra-
tion of systemic corticosteroids has greater benefit in the
presence of a blood eosinophil level of ≥2% vs a level
<2%).29,30 In this regard, two posthoc analyses of moder-
ate-to-very severe COPD reported fewer moderate and
severe exacerbations with eosinophil levels ≥2% than in
those with <2% if undergoing treatment with fluticasone
furoate/vilanterol vs vilanterol as monotherapy.31,32
Analysis of the data in these trials has strongly suggested
that blood eosinophil levels at baseline may, therefore,
represent a valid means to monitor the reduction of exacer-
bations with ICS/LABA in those with COPD and a clinical
history of moderate to severe exacerbations, as confirmed
in a recent review.33
Based on the available clinical evidence, high blood
levels of eosinophils can help predict future exacerbations,
and may also be related to a more favorable response to
ICS when added to LABA/LAMA, particularly so in those
with a clinical history of frequent exacerbations, even if
additional studies are still needed.34,35
ICS Withdrawal: Clinical Evidence
As noted in the review by Kaplan, despite the introduction
of ICS into clinical practice over 2 decades ago, the option
to continue or withdraw ICS in patients with COPD remains
somewhat unsubstantiated, with conflicting evidence.36 The
“step down” approach does not historically apply to COPD,
but the disproportionate and incongruous use of ICS in
COPD, along with the increased risk of associated adverse
events including pneumonia, strongly suggests that ICS
should be discontinued when the clinician deems that the
risks outweigh the possible benefits. In fact, the advantage
of ICS/LABA in combination compared to LABA alone in
prevention of exacerbations was strongly disputed in a
Cochrane meta-analysis several years ago.37 In 2017,
Calzetta carried out a meta-analysis of withdrawal of
inhaled corticosteroids in COPD wherein it was reported
that withdrawal of ICS did not significantly increase the rate
Dovepress Micheletto et al
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of exacerbations, even if a clinically relevant risk of severe
exacerbation was still present (RR >1.2).38 Moreover, with-
drawal of ICS led to significant impairment of both lung
function and quality of life, with a significantly shorter time
to first exacerbation in those who withdrew from ICS.
At least three studies have examined the consequences
of ICS withdrawal in real-life settings. In the first,
OPTIMO, there was no significant increase in the risk of
exacerbations during a 6-month period following disconti-
nuation of ICS vs continued therapy with ICS/bronchodila-
tor, and no evidence of deterioration in symptoms of COPD
or lung function.39 In agreement with this possibility, the
prospective, non-interventional 2-year DACCORD study
from Germany studied the consequences of ICS withdrawal
in 236 of 1022 patients with COPD.40 Patients in whom
ICS was withdrawn had shorter duration of disease and
better pulmonary function; among those in whom ICS was
withdrawn, 74.2% did not experience exacerbations, which
compares well with 70.7% among those continuing ICS;
over the first year, exacerbation rates were 0.414 in those
who withdraw and 0.433 in those who continued to
receive ICS.
Chapman et al, reported the results of a 6-month trial
investigating withdrawal of ICS in 1053 patients with
COPD and no history of frequent exacerbations or asthma,
but who were still being given triple therapy for ≥6
months.41 After a 4-week run-in on tiotropium, salmeterol,
and fluticasone propionate, patients were randomized to
either abrupt discontinuation of ICS and switch to a single
inhaler (IND/GLY) or to continue the same regimen.
Withdrawal of ICS led to a small non-significant decline
in FEV1 of 26 mL that occurred mostly with the first 4
weeks, and there was no increase in the rates of
exacerbation.
The WISDOM trial studied the effects of ICS with-
drawal on blood eosinophil count and exacerbations.42
Among the 2296 patients who received treatment follow-
ing ICS withdrawal, the rate of moderate or severe exacer-
bations was similar in the overall population, but greater
among those discontinuing ICS vs those continuing ICS in
patients who had eosinophil counts ≥2% (RR 1.22; [95%
CI 1.02–1.48]), ≥4% (RR 1.63; [1.19–2.24]) or ≥5% (RR
1.82; [1.20–2.76]). Thus, the increase seen in the rate of
exacerbations further augmented as the eosinophil cut-off
value increased. Interestingly, another analysis of the same
populations showed that only patients with >2 exacerba-
tions in the previous year and eosinophils >300 cells/μL
showed a significantly increased risk of exacerbations after
withdrawal of ICS.
The AFFIRM COPD (Aclidinium and Formoterol
Findings in Respiratory Medicine COPD) trial randomized
933 patients with moderate-to-severe COPD to aclidinium/
formoterol or salmeterol/fluticasone, both twice daily, over
a 24-week period.43 Aclidinium/formoterol was superior to
salmeterol/fluticasone when considering FEV1, showing a
mean increase of 93 mL with LAMA/LABA over salme-
terol/fluticasone. However, no difference between groups
was seen when considering exacerbations, dyspnea, or
quality of life.43
The recent FLAME trial directly compared LABA/
LAMA to the ICS/LABA combination.44 In this large
52-week study, 3360 patients with moderate-to-severe
COPD were randomized to twice-daily salmeterol and
fluticasone or once-daily IND/GLY. At 1 year, patients
who received IND/GLY experienced an 11% lower risk
of exacerbations vs those on salmeterol-fluticasone.
Moreover, IND/GLY therapy was associated with a longer
time to first exacerbation compared to those on salmeterol-
fluticasone [71 vs 51 days, 16% lower risk (p<0.001)],
fewer moderate and severe exacerbations, and lengthier
time to first moderate or severe exacerbation. Moreover,
compared to salmeterol-fluticasone, the effect of IND/GLY
on exacerbations was not dependent on eosinophil count at
baseline.
In a post hoc analysis of FLAME, IND/GLY provided
greater or similar prevention of exacerbation than salme-
terol-fluticasone in all groups when stratified by eosinophil
levels and exacerbation history, thus supporting the use of
the former to prevent exacerbations in moderate-to-very
severe COPD.45 Lastly, a subgroup analysis of the
FLAME study validated the consistent beneficial effects
of IND/GLY compared to salmeterol-fluticasone on mod-
erate/severe exacerbations that was not related to the his-
tory of exacerbations or treatment.46
Beyond FLAME
While the landmark trial FLAME trial showed greater
reduction in exacerbations with LABA/LAMA than
LABA/ICS in symptomatic patients with clinical history
of exacerbations, an analysis of this trial has suggested
that prevention of exacerbations with IND/GLY was similar
or possibly superior to that with salmeterol-fluticasone at all
ranges of eosinophil levels.47 This is in contrast to a post
hocanalysis of WISDOM, which insinuated that at least
some patients, namely those with history of exacerbations
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and high eosinophils levels, are at increased risk of exacer-
bations after ICS has been withdrawn.48 Another more
recent post hoc analysis of FLAME investigated the effects
of treatment on moderate to severe exacerbations consider-
ing both absolute (cut-offs of 150 and 300 cells/μL) and
percentage (2%, 3%, and 4%) blood eosinophil count, in
addition to exacerbation history (1 exacerbation and ≥2
exacerbations).49 At levels <150 cells/μL, IND/GLY
decreased the rate of moderate to severe exacerbations
compared to salmeterol-fluticasone in those with 1 and ≥2
exacerbations, while both treatments were similar in those
with ≥150 cells/μL and ≥300 cells/μL, independent of the
history of exacerbation. IND/GLY was consistently more
effective in the presence of low blood eosinophils, but has
comparable efficacy in groups with higher eosinophils. This
adds additional weight to the possibility that blood eosino-
phils can help to recognize patients who will likely benefit
from ICS and LABA/LAMA. The results of this post hoc
analysis further support the effectiveness of IND/GLY for
preventing exacerbations in patients with moderate-to-
severe COPD, and especially in those who are at greatest
risk for exacerbations, further confirming the validity of the
current GOLD guidelines that recommend LABA/LAMA
over LABA/ICS in patients with COPD and at risk of
exacerbations.17
Guidelines On ICS Use In COPD
Unfortunately, at present, there are no international guide-
lines that recommend how to perform withdrawal of ICS
or provide a protocol for withdrawal when deemed neces-
sary by the clinician; as the available data are not con-
clusive, more studies are needed to further understand in
which patients withdrawal of ICS can be considered to be
safe and beneficial.
In 2015, a consensus document from Spain was pub-
lished, agreeing that therapy with ICS should be added to
long-acting bronchodilators in the presence of frequent
exacerbations as well as in patients with ACOS; ICS should
not, however, be added to LABA to ameliorate pulmonary
function.50 Moreover, these experts further reached the con-
sensus that withdrawal of ICS in patients with stable disease
is possible, even if no consensus reached on how to achieve
this. Recommendations were mostly limited to stating that
withdrawal of ICS in COPD is possible, that patients dis-
continuing ICS should be monitored, and that tapering
should be used to withdraw ICS. Following changes to the
GOLD document in 2017, in which impaired lung function
is no longer considered as a determinant for risk of
exacerbation, many COPD patients can now be considered
to belong to group B, with a low risk of exacerbations and
clinically significant symptoms,17 and some considerations
have been made in this regard.51
Previous authors have attempted to provide algorithms
for withdrawing ICS in patients with COPD.36 The algo-
rithm proposed by Kaplan takes into consideration exacer-
bation risk, according to GOLD, but also the emergent
ACOS subgroup, as stated in the GINA/GOLD
Consensus Statement. The algorithm further considers
potential markers of eosinophilia, with a stepwise with-
drawal protocol using dual bronchodilators that is mainly
based on data from the WISDOM trial. Briefly, the algo-
rithm consists of 5 steps in which current management is
reviewed and the risk-benefits of continuing ICS therapy
are assessed, considering ACO, frequency of exacerba-
tions, and other potential markers such as eosinophils
(sputum ≥3%, blood eosinophils ≥300 cells/μL). A deci-
sion is then made to withdraw (or not) ICS therapy. If
withdrawn, a stepwise approach is taken, with possible
step-up and step-down of ICS doses. Bronchodilation ther-
apy with LABA/LAMA is optimized, and patients are
followed regularly every 3 months. While oversimplified
in the present discussion, other authors have held that such
a proposal is somewhat complex and difficult to adopt in
daily clinical practice.52
As such, other algorithms have been recently devel-
oped. The first is a simple treatment algorithm for inhaled
pharmacotherapy based on dyspnea.53 Patients are sub-
grouped based on the presence of low (<2 mMRC dyspnea
scale) or high (≥2 mMRC dyspnea scale) dyspnea. If the
patient has a low score, one long-acting bronchodilator is
given, while two bronchodilators are given if the patient
has a high score. In the presence of ≥2 exacerbations in the
prior year (keeping in mind that even a patient with one
severe exacerbation and hospitalization is considered a
frequent exacerbator), ICS are added to treatment, inde-
pendently of the degree of dyspnea. The algorithm was
also validated on 100 patients who were receiving care in
primary and tertiary settings.
In a second simplified algorithm proposal, the choice
of withdrawing or continuing ICS is initially based on
stratification for the presence of ACO.52 In patients with
FEV1 >50% and without previous exacerbations, ICS
should be discontinued. In those with ACO and who had
exacerbations in the prior year, the benefits exceed the
risks associated with withdrawal of ICS. Patients with
FEV1 > 50% and exacerbations in the prior year as well
Dovepress Micheletto et al
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as those with FEV1 < 50% without exacerbations should
be carefully evaluated for withdrawal of ICS. As such,
therapy with a dual bronchodilator should be continued
to ensure that there is no increase in the risk of exacerba-
tions. In patients with FEV1 < 50% and exacerbations in
the prior year, as well as in those with ACO and no
exacerbations, discontinuation of ICS should only be con-
sidered in those who have a substantial risk of serious side
effects related to use of ICS. Close follow-up is essential.
Shortcomings In Daily Practice
In line with current clinical practice guidelines for COPD,
the addition of ICS to long-acting β2 agonist therapy is
advocated only in those with moderate-to-severe disease
who are at increased risk of exacerbations, even if fixed-
dose combinations of ICS/LABA are often used in contra-
diction of current recommendations in patients who are at
a low risk of exacerbations. The available evidence from
controlled trials adds weight to the supposition that ICS
can be reasonably discontinued, from both safety and
efficacy standpoints, in patients with stable COPD and in
those for whom ICS therapy is not indicated; in the major-
ity of patients, discontinuation is not likely to have unfa-
vorable effects on pulmonary function, overall health
status, or lead to a greater risk of exacerbations. Due to
the lack of international guidelines, several groups have
proposed algorithms for withdrawing ICS in patients with
COPD. While the complexity of these algorithms may
differ, all adhere to the principles of the most recent
GOLD guidelines, even if their solid validation remains a
weak point for their implementation. Nonetheless, all are
also based on the underlying principle that ICS therapy is
related to an increased risk of potentially serious adverse
effects and complications, and as such, its use should be
restricted to a minority of patients after careful evaluation
of the individual risk-benefit profile.
Deprescribing ICS In Routine
Practice
Following withdrawal of ICS, dual bronchodilator therapy
should continue and patients should be carefully watched.
Moreover, ICS therapy may be discontinued either
abruptly or via gradual dose reduction in a stepwise fash-
ion, but in any case, close monitoring is essential. Patients
should not experience a decline in lung function during
withdrawal. Particular care is warranted in high-risk
patients who have frequent exacerbations or in patients
with poor pulmonary function and being given a high
dose of ICS. This is especially true when considering
initiating a patient on ICS therapy or the discontinuation
of ICS in patients who are already on long-term therapy.
While promising, the role of elevated blood eosinophils as
a marker to identify patients for treatment with ICS is still
being debated, and further clinical studies are needed.
Indeed, the available data support a role for ICS in the
presence of eosinophil levels ≥300 cells/µL. In the absence
of unequivocal guidance, clinicians should continue to
carefully evaluate and treat patients on an individual basis.
Current GOLD Recommendations
The GOLD 2019 strategy proposed a strategy for initiating
pharmacological treatment of COPD that utilizes individua-
lized evaluation of symptoms and exacerbations; ICS are
considered as the first choice only in some GOLD D
patients with particular characteristics such as blood eosi-
nophil ≥300 cells/µL (in treatment-naïve patients) or history
of asthma (Figure 1).3 This recommendation anyway comes
together with the alert of possible development of pneumo-
nia, so that ICS should be used during initial therapy only
after considering its potential benefits and risks. The current
GOLD 2019 strategy recommends a 3-step review for
assessment and adjustment for which escalation, or switch-
ing the inhaler device or agent used within the same class
may be considered as appropriate. The patient’s response to
escalation of treatment should always be monitored, and de-
escalation should be taken into consideration when there is
no clinical benefit and/or in the presence of side effects.
Clinicians can also consider de-escalation in patients with
COPD who are receiving treatment and who have some
symptoms that may require less intensive treatment, but in
any can should this should be undertaken under close med-
ical supervision. ICS withdrawal is currently recommended
in COPD patients who experience adverse effects from ICS
treatment as well as patients with inappropriate ICS treat-
ment or those not showing benefits from the same treat-
ment. Unfortunately, GOLD recommendations do not
provide any suggestion on how to do this withdrawal
(abruptly or with ICS dose tapering, even if off-label) and
what phenotype of patients should be considered for this
therapeutic re-organization. In this regard, one might con-
sider ICS withdrawal in those with low eosinophil counts,
no ACO, or ICS-related adverse events.
Interestingly, the IPCRG group has recently issued an
algorithm for ICSwithdrawal by simply assessing if the patient
has asthma features or high exacerbation risk, and gives
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recommendations on the possibility to continue ICS treatment
or to re-organize COPD maintenance treatment in favor of a
double bronchodilator treatment (with no ICS added).54
Proposal Of A Simple Management
Tool For COPD
Within the context of the above, an easy tool that gives
physicians a support to guide the most appropriate COPD
management seems particularly useful (Figure 2). The
question of if not needed “the ICS should be abruptly
withdrawn or the dose should be reduced gradually until
full withdrawal” has no strong evidence-based answer at
this time. What is important is the acknowledgement of a
need to re-evaluate treatment for all COPD patients and in
light of the ancient principle “first do not harm” any
unnecessary or potentially harmful treatment should be
withdrawn, to put in practice the therapeutic re-organiza-
tion that aims to a personalized medicine that is currently
quite far from COPD management in routine clinical
practice. Lastly, it should be noted that the proposed tool
was not developed using formal methodology, but rather
on clinical experience and review of the literature. It has
also not escaped our attention that the simple tool pro-
posed will require formal validation.
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